Expert OpinionPharma/Biotech Clinical
FDA Grants Traditional Approval To Eli Lilly And Co Pirtobrutinib For Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma
Benzinga•December 03, 2025 at 5:38 PM•Full Content
View Original →📊 Workflow Status
✓ CompletedCompleted in 17s
clean_raw_article
✓ completed→
clean_markdown_article
✓ completed→
analyze_article
✓ completed→
link_article_to_stories
⊘ skipped→
analyze_sentiment
✓ completedWorkflow #1672 • Benzinga Article Processing
Started: 17:39:00 • Completed: 17:39:18
View Details →Detected Companies & Sentiment
Eli Lilly and Company
"strong positive momentum"
9
Gist
The FDA has granted traditional approval to Eli Lilly's pirtobrutinib for treating chronic lymphocytic leukemia and small lymphocytic lymphoma, marking a significant milestone in cancer therapy.
LLM Summary
The U.S. FDA has granted traditional approval to Eli Lilly's pirtobrutinib for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), particularly those who have progressed on prior BTK inhibitors. This approval is based on clinical trial data demonstrating efficacy and safety. The decision supports pirtobrutinib as a key treatment option in a difficult-to-treat patient population.
Full Article Content
Metadata
Author:
Benzinga Newsdesk
Tickers:
LLY
Updated At:
December 03, 2025 at 1:38 PM
Benzinga Channels:
Biotech, News, General
Teaser:
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic
Benzinga Stocks:
LLY (NYSE)
Benzinga Article ID:
49190877